Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

Sarah Uboldi, I. Craparotta, G. Colella, E. Ronchetti, L. Beltrame, S. Vicario, S. Marchini, Nicolò Panini, G. Dagrada, F. Bozzi, S. Pilotti, C. M. Galmarini, M. D'Incalci, R. Gatta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be described as a member of the family of small round blue cell tumors. The molecular diagnostic marker is the t(11;22)(p13;q12) translocation, which creates an aberrant transcription factor, EWS-WT1, that underlies the oncogenesis of DSRCT. Current treatments are not very effective so new active drugs are needed. Trabectedin, now used as a single agent for the treatment of soft tissue sarcoma, was reported to be active in some pre-treated DSRCT patients. Using JN-DSRCT-1, a cell line derived from DSRCT expressing the
Original languageUndefined/Unknown
Pages (from-to)107
Number of pages1
JournalBMC Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - Feb 1 2017

Keywords

  • DSRCT, JN-DSRCT-1, Trabectedin

Cite this

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells. / Uboldi, Sarah; Craparotta, I.; Colella, G.; Ronchetti, E.; Beltrame, L.; Vicario, S.; Marchini, S.; Panini, Nicolò; Dagrada, G.; Bozzi, F.; Pilotti, S.; Galmarini, C. M.; D'Incalci, M.; Gatta, R.

In: BMC Cancer, Vol. 17, No. 1, 01.02.2017, p. 107.

Research output: Contribution to journalArticle

Uboldi, S, Craparotta, I, Colella, G, Ronchetti, E, Beltrame, L, Vicario, S, Marchini, S, Panini, N, Dagrada, G, Bozzi, F, Pilotti, S, Galmarini, CM, D'Incalci, M & Gatta, R 2017, 'Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.', BMC Cancer, vol. 17, no. 1, pp. 107. https://doi.org/10.1186/s12885-017-3091-1
Uboldi, Sarah ; Craparotta, I. ; Colella, G. ; Ronchetti, E. ; Beltrame, L. ; Vicario, S. ; Marchini, S. ; Panini, Nicolò ; Dagrada, G. ; Bozzi, F. ; Pilotti, S. ; Galmarini, C. M. ; D'Incalci, M. ; Gatta, R. / Mechanism of action of trabectedin in desmoplastic small round cell tumor cells. In: BMC Cancer. 2017 ; Vol. 17, No. 1. pp. 107.
@article{0f167faaea664011a5514fc459e25e79,
title = "Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.",
abstract = "BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be described as a member of the family of small round blue cell tumors. The molecular diagnostic marker is the t(11;22)(p13;q12) translocation, which creates an aberrant transcription factor, EWS-WT1, that underlies the oncogenesis of DSRCT. Current treatments are not very effective so new active drugs are needed. Trabectedin, now used as a single agent for the treatment of soft tissue sarcoma, was reported to be active in some pre-treated DSRCT patients. Using JN-DSRCT-1, a cell line derived from DSRCT expressing the",
keywords = "DSRCT, JN-DSRCT-1, Trabectedin",
author = "Sarah Uboldi and I. Craparotta and G. Colella and E. Ronchetti and L. Beltrame and S. Vicario and S. Marchini and Nicol{\`o} Panini and G. Dagrada and F. Bozzi and S. Pilotti and Galmarini, {C. M.} and M. D'Incalci and R. Gatta",
year = "2017",
month = "2",
day = "1",
doi = "10.1186/s12885-017-3091-1",
language = "Non definita",
volume = "17",
pages = "107",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

AU - Uboldi, Sarah

AU - Craparotta, I.

AU - Colella, G.

AU - Ronchetti, E.

AU - Beltrame, L.

AU - Vicario, S.

AU - Marchini, S.

AU - Panini, Nicolò

AU - Dagrada, G.

AU - Bozzi, F.

AU - Pilotti, S.

AU - Galmarini, C. M.

AU - D'Incalci, M.

AU - Gatta, R.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be described as a member of the family of small round blue cell tumors. The molecular diagnostic marker is the t(11;22)(p13;q12) translocation, which creates an aberrant transcription factor, EWS-WT1, that underlies the oncogenesis of DSRCT. Current treatments are not very effective so new active drugs are needed. Trabectedin, now used as a single agent for the treatment of soft tissue sarcoma, was reported to be active in some pre-treated DSRCT patients. Using JN-DSRCT-1, a cell line derived from DSRCT expressing the

AB - BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be described as a member of the family of small round blue cell tumors. The molecular diagnostic marker is the t(11;22)(p13;q12) translocation, which creates an aberrant transcription factor, EWS-WT1, that underlies the oncogenesis of DSRCT. Current treatments are not very effective so new active drugs are needed. Trabectedin, now used as a single agent for the treatment of soft tissue sarcoma, was reported to be active in some pre-treated DSRCT patients. Using JN-DSRCT-1, a cell line derived from DSRCT expressing the

KW - DSRCT, JN-DSRCT-1, Trabectedin

U2 - 10.1186/s12885-017-3091-1

DO - 10.1186/s12885-017-3091-1

M3 - Articolo

VL - 17

SP - 107

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

ER -